Protara Therapeutics, Inc.
TARA
$3.97
-$0.07-1.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.56% | 25.59% | 20.10% | 13.39% | 1.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.22% | 31.32% | 30.29% | 29.60% | 12.45% |
| Operating Income | -36.22% | -31.32% | -30.29% | -29.60% | -12.45% |
| Income Before Tax | -39.40% | -28.80% | -25.81% | -25.00% | -6.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.40% | -28.80% | -25.81% | -25.00% | -6.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.40% | -28.80% | -25.81% | -25.00% | -6.93% |
| EBIT | -36.22% | -31.32% | -30.29% | -29.60% | -12.45% |
| EBITDA | -36.38% | -31.47% | -30.54% | -29.85% | -12.58% |
| EPS Basic | 21.65% | 44.44% | 48.84% | 48.80% | 53.83% |
| Normalized Basic EPS | 21.64% | 44.45% | 48.85% | 48.81% | 53.83% |
| EPS Diluted | 21.65% | 44.44% | 48.84% | 48.80% | 53.83% |
| Normalized Diluted EPS | 21.64% | 44.45% | 48.85% | 48.81% | 53.83% |
| Average Basic Shares Outstanding | 69.93% | 110.39% | 128.62% | 137.94% | 143.62% |
| Average Diluted Shares Outstanding | 69.93% | 110.39% | 128.62% | 137.94% | 143.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |